AI Summary
The title suggests that researchers have discovered new inhibitors for DOT1L R231Q, a non-nucleoside enzyme involved in cancer. These inhibitors have improved pharmacokinetic properties, meaning they are more efficiently absorbed, distributed, metabolized, and excreted by the body. They also show anti-lung cancer efficacy, indicating they may be effective in treating lung cancer. The findings are significant as they may lead to the development of more effective treatments for lung cancer.